Quinagolide in hyperprolactinaemia

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 1, 1998, Pages 1-75

  Brownell, Judith ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; METERGOLINE; PERGOLIDE; PROLACTIN; QUINAGOLIDE;

ACROMEGALY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; LIBIDO; MALE; MENSTRUATION; MICROADENOMA; NAUSEA; PARKINSON DISEASE; REVIEW; TUMOR VOLUME; VERTIGO;

EID: 0031908933     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Abrahamson MJ, Handler L, Isaacs M. Effects of CV 205-502 on growth hormone and prolactin secretion in acromegaly and hyperprolactinaemic states including micro- and macroprolactinomas. J Endocrinol Invest 1991; 14 (Suppl 1): 105.
2. Adams EF, Brajkovich IE, Mashiter K. Hormone secretion by dispersed cell cultures of human pituitary adenomas: effects of theophylline, thyrotropin-releasing hormone, somatostatin and 2-bromo-a-ergocryptine. J Clin Endocrinol Metab 1979; 49: 120-126.
3. Adams EF, Bhuttacharji SC, Halliwell CLJ, Loizou M, Birch G, Mashiter K. Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumours in cell culture. Clin Endocrinol 1984; 21: 709-718.
4. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981; 11: 237-243.
5. Allolio B, Höppner A, Leonhardt U, Deuss U, Winkelmann W. Size heterogeneity of immunoreactive prolactin in patients with prolactinoma. Acta Endocrinol 1987; 114: 475-482.
6. Andersen AN, Pedersen H, Djursing H, Andersen BN, Friesen HG. Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception. Fertil Steril 1982; 38: 625-628.
7. Anfossi G, Massuco P, Mularoni M et al. Studies on the effect of dopamine on the human platelet response. Clin Exp Pharmacol Physiol 1992; 19: 613-618.
8. Angrist B. Psychosis induced by central nervous system stimulants and related drugs. In: Creese I, ed. Stimulants: neurochemical, behavioural and clinical perspectives. New York: Raven Press, 1983: 1-30.
9. Winkelmann W, Allolio B, Heesen D, Jaursch-Hancke C, Kaulen D, Reincke M. Impaired regulation of prolactin in patients with persisting normopro-lactinaemia after withdrawal of long-term therapy with dopamine agonists. In: Landolt AM, Heitz PU, Zapf J, Girard J, Del Pozo E, eds. Advances in pituitary adenoma research. Oxford: Pergamon Press, 1988: 321-324.
10. Wollesen F, Bjerg Bendsen B. Effect rates of different modalities for treatment of prolactin adenomas. Am J Med 1985; 78: 114-122.
11. Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 1982; 96: 281-286.
12. 2 receptor and pituitary tumours. Clin Endocrinol 1991; 35: 455-466.
13. Woolf PD, Lee LA, Leebaw WF. Hypoglycemia as a provocative test of prolactin release. Metabolism 1978; 27: 869-877.
14. Yen SCC, Rebar R, Vandenberg G, Judd H. Hypothalamic amenorrhea and hypogonadotropism. J Clin Endocrinol Metab 1973; 36: 811-816.
15. Yeo T, Thorner MO, Jones A, Lowry PJ, Besser GM. The effects of dopamine, bromocryptine, lergotrile and metoclopramide on prolactin release from continuously perifused columns of isolated rat pituitary cells. Clin Endocrinol 1979; 10: 123-130.
16. Zanella MT, Bessa AM, Saragoca MA, Ribeiro AP, Ramos DL. Acute hemodynamic and humoral effects of metoclopramide in orthostatic hypotension. Clin Invest Med 1983; 6 (Suppl 2): 37.
17. Ziegler MG, Lake CR, Williams AC, Teychenne PF, Schoulson I, Steinsland O. Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 1979; 25: 137-142.